Participated · Series B · Apr 2024

Alterome leverages its Kraken structure-guided, machine-learning drug discovery platform to design mutation-selective and isoform-selective small-molecule therapies. Its preclinical pipeline features a covalent AKT1 E17K mutation-selective inhibitor and a KRAS isoform-selective inhibitor designed to address approximately 90% of KRAS mutations, including G12V and G12D. The company emphasizes precision approaches intended to target cancer cells over normal cells to increase inhibition of key drivers while improving safety. Alterome recently closed a $132 million Series B financing to advance multiple wholly owned programs. Proceeds will be used to support advancing lead programs into the clinic, with the AKT1 and KRAS programs expected to begin clinical testing within the next 12 months. The company is led by an experienced precision oncology R&D team and is based in San Diego. Alterome Therapeutics is a precision oncology biotech developing alteration-specific targeted therapies to treat cancer. The company designs its pipeline programs using an in-house computational chemistry platform called “The Kraken,” which provides atomic-level insights and predicts ligand activity and binding modes. Its current pipeline comprises three next-generation precision oncology programs that the company plans to advance with the new financing. Management emphasizes a blend of computational chemistry, medicinal chemistry, and translational biology to design highly selective therapeutics against validated oncogenic drivers. The company is led by founder, CEO and CSO Eric Murphy, Ph.D., and an R&D team with experience in developing marketed oncology small-molecule drugs. Financially, Alterome has raised nearly $100 million to date following the latest extension to its Series A. Alterome Therapeutics is a precision oncology biotechnology company focused on developing alteration-specific therapeutics that target high-value, validated oncogenic drivers. The company is building targeted, alteration-specific medicines intended to advance the precision oncology field and transform treatment paradigms for cancer patients. Leadership is headed by co-founder Eric Murphy, Ph.D., who will serve as chief executive and chief scientific officer, and co-founder Ryan Corcoran, M.D., Ph.D., who will serve on the board and scientific advisory board. The team emphasizes seasoned R&D leaders with a history of developing marketed oncology small-molecule drugs. Alterome positions its scientific approach to address validated oncogenic drivers and pursue precision-targeted cancer therapies.

Led · Series B · Feb 2024

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, CA that focuses on designing and developing novel targeted medicines for difficult-to-treat cancers. Its science-driven approach addresses specific oncogenic drivers to improve patient outcomes. The company’s two lead clinical assets are BH-30643, a first-in-class, macrocyclic, non-covalent, mutant-selective OMNI-EGFRTM inhibitor aimed at EGFR- or HER2-mutated non-small cell lung cancer, and BH-30236, a macrocyclic CLK inhibitor targeting relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndrome. BlossomHill plans to use fresh capital to accelerate clinical development of these programs and to progress its wholly owned pipeline of designed cancer medicines. Since inception, the company has raised a total of $257 million in equity funding, most recently via a Series B extension. No operating metrics such as revenue or patient enrollment figures were disclosed in the article.

Participated · Series C · Dec 2023

Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to precisely target disease pathology in autoimmune and inflammatory diseases. Since its founding in 2021, the company has built comprehensive drug discovery and development capabilities and advanced an internally discovered program through multiple clinical milestones. Odyssey has nominated multiple development candidates and established collaborations with pharmaceutical leaders and biotech innovators. Its portfolio includes internally discovered clinical and preclinical candidates intended to induce deep and durable remission across several inflammatory diseases with unmet need. The company plans to advance these programs toward important clinical milestones and translate scientific efforts into patient benefit. Odyssey recently completed a major financing to support progression of its clinical pipeline. Odyssey Therapeutics has built a discovery and development platform that merges computational and experimental technologies to identify modality-agnostic drug targets with high clinical potential. From its Boston headquarters, the company has advanced multiple programs from ideation to a portfolio of high-value product candidates within about two years of founding in late 2021. Odyssey is focused on bringing immunology and oncology therapeutics into clinical development, with several molecules that could enter the clinic in the next 12 months. Proceeds from financing will support advancement of multiple programs into clinical studies and continued investment in discovery to build a sustainable model for therapeutic innovation. The company emphasizes a capital-efficient model and aims to deliver safe and effective precision medicines to patients with serious diseases. Leadership includes founder and CEO Gary D. Glick, Ph.D., and an experienced board guiding clinical and company-building strategy. Odyssey Therapeutics, based in Boston, raised $168M in a Series B funding round led by General Catalyst. The round included participation from Fidelity Management & Research Company, T. Rowe Price Associates, GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, The Healthcare Innovation Investment Fund LLC, OrbiMed, SR One, Foresite Capital, Logos Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures and Creacion Ventures. The company intends to use the funds to advance its portfolio of precision immunomodulators and oncology medicines. Its immunology and oncology portfolio encompasses eight declared programs initially focused on small molecule and protein therapeutics. Odyssey is building a discovery engine that integrates artificial intelligence and machine learning for molecular design, a chemistry platform encompassing proprietary covalent libraries targeting multiple amino acids, molecular glues and natural products, and a functional genomics platform for novel target discovery. Gary D. Glick, Ph.D. is Founder and Chief Executive Officer. Odyssey Therapeutics develops next-generation precision immunomodulators and oncology medicines using a discovery platform that combines target biology, medicinal and structural chemistry, physics-based molecular simulations, and AI/machine learning. The company was founded by Gary D. Glick, Ph.D., and is led by a team with a track record that includes helping bring more than 20 drugs to market. Odyssey intends to advance multiple pipeline programs and expand its discovery platform to broaden the druggable genome. Financially, the company completed a large Series A financing (see deal details). Odyssey is headquartered in Boston, with labs there, and is expanding its team to more than 90 scientists and staff. The company emphasizes selecting targets and therapeutic modalities aimed at maximizing clinical impact.

Participated · Series B · Oct 2021

ReCode Therapeutics is a clinical-stage biotech developing genetic medicines for cystic fibrosis, leveraging its Selective Organ Targeting lipid nanoparticle delivery platform alongside mRNA and gene-editing approaches. Its lead inhaled program, RCT2100, is in a fully enrolled Phase 2a study and received Fast Track designation from the U.S. FDA in February 2026, with data expected in the fourth quarter. The company has entered a research collaboration with an undisclosed gene-editing company to co-develop therapies that correct CFTR mutations, combining ReCode's delivery technology with the partner's editing platform. The collaboration and funding from the Cystic Fibrosis Foundation are intended to advance one or more candidates toward clinical development and commercialization. Recent leadership changes include Heather Clark being named CEO and former CEO Shehnaaz Suliman becoming executive chair of the board. Clark joined ReCode in 2022 and has extensive rare-disease and cystic fibrosis drug development experience, including more than two decades at Vertex Pharmaceuticals.

Participated · Series B · Apr 2020

Erasca is a San Diego–based precision oncology company founded in 2018 that advances multiple targeted cancer programs. The company pursues in-house drug discovery to develop precision therapies directed at undisclosed targets and expands its pipeline via academic and biopharmaceutical collaborations. Erasca has assembled a portfolio of potentially first‑in‑class and best‑in‑class assets aimed at significant unmet medical needs across multiple cancer types. The company will use the new financing to fund clinical development of multiple oncology programs, continue corporate development efforts, and further advance its in‑house discovery pipeline. Erasca has raised $300 million in total capital to date, including a Series B that has been extended to $236 million. Investors named in the announcement include ARCH Venture Partners, City Hill Ventures, Cormorant Asset Management, and new participants Partner Fund Management and OrbiMed. Erasca is focused on developing targeted therapies that shut down key cancer pathways. The company advances multiple in-house drug discovery programs directed at undisclosed targets and pursues in-licensing and collaborations to expand its pipeline. Management says it has assembled a proven team and world-class collaborators and has made substantial progress since commencing operations just 18 months ago. Erasca will use financing proceeds to support clinical development of multiple oncology programs and to further advance its discovery pipeline. Financially, the company has raised more than $260 million to date, including the newly announced round. Its stated mission is to "erase cancer" and it targets both potentially first-in-class and best-in-class assets to address unmet needs in oncology. Erasca is developing oncology therapeutics using computational and biological approaches to target core drivers of cancer. The company operates multiple discovery programs for undisclosed biological targets and pursues pipeline expansion through academic and biopharmaceutical collaborations. Its proprietary OPRA (Oncology Pattern Recognition Algorithm) AI platform leverages machine learning and large-scale datasets to elucidate tumor biology and prioritize therapeutic strategies, including single-agent and combination approaches. Erasca plans to use new funds to potentially in-license investigational compounds and accelerate OPRA’s buildout to drive discovery and development of next-generation oncology drugs. Financially, the company completed a Series A extension that brought total Series A proceeds to $64M. Erasca, founded in 2018 and based in San Diego, is focused on advancing scientific approaches to erase cancer by developing a new generation of oncology drugs. The company has multiple discovery programs underway targeting biological drivers of cancer, though the specific targets are undisclosed. Erasca intends to use its financing proceeds to advance drug development and move programs into human clinical studies. It anticipates disclosing more about those programs as it progresses into clinical trials. The company is also pursuing pipeline expansion through academic and biopharmaceutical collaborations. Leadership includes founder Jonathan E. Lim, M.D., with Gary Yeung, CFA, as Chief Business Officer and Robert Shoemaker, Ph.D., as Vice President of Biology.